Tonix Pharma

Q2 FY2026 EarningsQ2 FY26 results significantly beat consensus on both top and bottom lines: revenue was $13.5M vs. $7.7M expected, and GAAP EPS was -$2.44 vs. -$2.71 expected. Growth was primarily driven by the commercial launch of TONMYA, which achieved $11M in net sales (up 197% QoQ). While SG&A and R&D expenses rose significantly to support launch and pipeline activities, the higher-than-expected revenue and improved product mix narrowed losses relative to analyst projections.